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The Problem
Do We Already Have Too Many
Cancer Biomarker Candidates?
Although there is intense activity to-
wards identifying novel biomarkers for
cancers, especially those for early detec-
tion, it is not clear whether we already
have too many biomarkers described in
the literature. Given that there is no
central repository of data pertaining to
any cancer, it is difficult to estimate if we
have too many proteins described as
‘‘potential biomarkers’’ for any cancer.
Technological advances in genomics, tran-
scriptomics, and proteomics have facilitat-
ed high-throughput studies in which the
data are analyzed in isolation and a
comparison with the published literature
is not generally feasible for the entire
dataset. A central repository will not only
integrate all the information scattered
across the literature, but will also serve as
a reference for prioritizing and systematic
testing of candidate biomarkers. Pancreat-
ic cancer is a deadly disease for which the
available biomarkers, such as CA19-9,
lack the desired sensitivity and specificity
for early detection [1]. Therefore, we took
pancreatic cancer as a model and carried
out a comprehensive literature survey to
systematically catalog the overexpressed
genes/proteins. Our objective was to
develop a compendium of potential bio-
markers that could be systematically
validated by the pancreatic cancer com-
munity and serve as a prototype for similar
efforts in other cancers.
Strategy
With a large number of studies in the
published literature (a keyword search for
‘‘pancreatic cancer’’ fetches ,50,000 pub-
lished articles), our approach (Figure 1)
was to first identify the relevant publica-
tions and datasets (e.g., microarray data
submitted to repositories such as GEO,
ArrayExpress, and Oncomine [2–4]) that
might contain information on overexpres-
sion of mRNAs or proteins in pancreatic
cancer. The type of pancreatic cancer and
the cell type where overexpression was
observed were also annotated. After gen-
erating this list of molecules, specific
searches were carried out to identify the
presence of these molecules in body fluids
or on the plasma membrane. Finally,
queries were carried out to determine the
status of these molecules in chronic
pancreatitis, which is an important con-
sideration in the differential diagnosis of
pancreatic cancer.
Inclusion Criteria for Candidate
Biomarkers of Pancreatic Cancer
Figure2showsthecriteriaforinclusionof
moleculesinthiscompendium.For anentry
to be considered with evidence of overex-
pression at the mRNA level, there had to be
a minimum of 2-fold overexpression in
cancerascomparedtonormalsamples.This
is an arbitrary cut-off and was used mainly
because it is the most common cut-off used
byauthorsofsuchstudies. DNA microarray
data in which the fold changes were not
specified were not included in the list.
However, molecules that had a fold change
of less than two were included if they were
reported to be overexpressed by multiple
methods. For the protein-level evidence, a
protein was included if the quantitative
proteomics was used (e.g., ICAT, iTRAQ,
or SILAC methods) with a greater than 2-
fold change. Molecules identified from non-
quantitative proteomics methodologies (in-
cluding 2-D gels) were included only if they
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as Western blotting, immunohistochemical
labeling, or ELISA. Molecules without any




Overexpressed in Pancreatic Cancer
A total of 2,516 genes are included in this
compendium, which includes molecules
with evidence of overexpression at mRNA
level, protein level, or both (see Table 1 for
summary statistics). A total of 1,868 genes
were reported as overexpressed only in the
mRNA analyses, while 441 were reported as
overexpressed both at mRNA and protein
levels, and 207 molecules were reported as
overexpressed only at the protein level.
More than 200 genes are reported to be
overexpressed in pancreatic cancers in four
or more studies, making them excellent
candidates for focused validation. Table A in
Table S1 is a list of select molecules that are
overexpressed in pancreatic ductal adeno-
carcinoma (PDAC, the most common type
of pancreatic cancer), and that have been
demonstrated by multiple methods at
mRNA and protein levels. All molecules
listed in this table are membrane-associated
or secreted molecules and have immunohis-
tochemical evidence, which makes them
more reliable as potential biomarkers.
Secreted and Membrane Proteins
Overexpressed in PDAC
For clinical screening of a potential
biomarker, it is difficult to obtain tissue as
a specimen since it requires an invasive
procedure and a biopsy. Thus, it is
desirable to have markers that could be
detected in serum or other accessible body
fluids such as urine. We cataloged studies
in which the overexpressed molecules were
detectable in body fluids by specific
searches of the literature and from another
community resource that we have recently
developed called Human Proteinpedia [5].
The compendium provides a total of 162
secreted molecules that are overexpressed
in pancreatic cancers at both RNA and
protein levels. A select list of secreted
proteins with multiple lines of evidence
describing overexpression in pancreatic
cancers at mRNA and protein levels,
along with their detectability in body
fluids, is provided in Table B in Table
Figure 1. The curation protocol for generating the catalog of potential biomarkers. The curation protocol was entirely based on the
published articles and data submitted to public repositories. Along with the list of molecules that are overexpressed in pancreatic cancers, literature
evidence for their presence in plasma membrane and detectability in body fluids like serum was also searched for. The list includes overexpression
studies from both endocrine and exocrine neoplasms of the pancreas.
doi:10.1371/journal.pmed.1000046.g001
Figure 2. Criteria for inclusion as a potential biomarker. The primary criterion in compiling candidate biomarkers of pancreatic cancer was to
identify molecules with an experimental evidence of overexpression either at mRNA or protein levels from the published literature. All molecules
included in the list of potential biomarkers were required to have a minimum of 2-fold overexpression in cancer as compared to normal. Proteins
reported to be overexpressed based on non-quantitative proteomic experiments were included only when there was additional evidence by
alternative methods. Candidates from studies using antibody-based strategies like immunohistochemistry (IHC), ELISA, and Western blots were
included without regard to fold changes, provided they were reported to be overexpressed in cancer as compared to normal.
doi:10.1371/journal.pmed.1000046.g002
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majority of drug targets in use and are
also attractive because of their potential
use in cancer imaging and targeted
therapeutic strategies. Also, plasma mem-
brane-bound proteins are often shed into
the bloodstream, which makes them useful
candidates as biomarkers for early detec-
tion. Thus, focusing on membrane pro-
teins overexpressed in pancreatic cancers
could considerably enhance the chances of
detecting and/or treating pancreatic can-
cer lesions at an early stage. The compen-
dium lists 166 membrane molecules that
are overexpressed in pancreatic cancers at
both RNA and protein levels. A partial list
of cell surface proteins with multiple
reports of overexpression in pancreatic
cancers at both mRNA and protein levels
is provided in Table C in Table S1.
Precursor Lesions
Pancreaticintraepithelial neoplasia (Pan-
IN), intraductal papillary mucinous neo-
plasms (IPMNs), and mucinous cystic
neoplasms are well-defined precursor le-
sions of invasive pancreatic cancer [6]. The
genes overexpressed in these potentially
curable precursor lesions would be ideal for
early detection of pancreatic neoplasia.
Global gene expression profiling studies
using microdissected precursor lesions have
revealed that there are several differences,
but also commonalities, in gene expres-
sion between these precursor lesions and
invasive PDACs [7]. Nearly 1,100 mole-
cules have been reported to be overex-
pressed in PanINs and IPMNs. A large
majority of these molecules show elevated
e x p r e s s i o ni nP D A C sa sw e l la sp r e c u r s o r
lesions. For example, molecules such as
S100P, MMP7, MUC4, FSCN1, and
MUC5AC are overexpressed in PanINs
a n dI P M N s ,a sw e l la sP D A C s .A l lo f
them have been investigated by several
methods including immunohistochemical
labeling. Table D in Table S1 shows a
partial list of molecules overexpressed in
precursor lesions and their status in
PDACs, if reported. As most of the
protein molecules listed in Table D in
Table S1 are detectable in body fluids,
targeted studies to confirm the specificity
of their expression pattern in precursor
l e s i o n sa n dP D A C sc o u l dp r o v i d ee a r l y
diagnostic markers with higher specificity
and sensitivity. Particular caution should
be taken while considering molecules
observed in PanINs as early diagnostic
markers of pancreatic cancer. While
PanINs have been observed to progress
into infiltrating carcinoma in some in-
stances, it is not known how often or how
rapidly they progress. Further, lower-
grade PanINs (PanIN-1 and PanIN-2)
are common in the older adult popula-
tion, with a limited number of cases
known to go on to develop cancer. Thus,
biomarkers specific to PanIN-3 would
prove useful as early diagnostic markers
of pancreatic cancers. Continued efforts
to study early stages of pancreatic cancer
are therefore vital in identifying markers
for early diagnosis.
Chronic Pancreatitis
Chronic pancreatitis is an inflammatory
condition whose symptoms can be similar
to those associated with pancreatic cancer,
and there are no good biomarkers to
distinguish these two conditions [8]. Al-
though it is uncommon for pancreatic
cancer cases to be mistaken for pancrea-
titis, there is occasional difficulty in
clinically distinguishing chronic pancreati-
tis from pancreatic cancer. Often, pancre-
atic cancer obstructs the pancreatic duct
and causes an obstructive form of pancre-
atitis. Thus, biomarkers that can distin-
guish these two clinical conditions are
desirable. This compendium has 372
molecules reported to be overexpressed
in chronic pancreatitis. A partial list of
molecules overexpressed in chronic pan-
creatitis is provided in Table E in Table
S1. Many of the molecules overexpressed
in chronic pancreatitis are also overex-
pressed in pancreatic cancer. For example,
EPH receptor A3 and fibrillin 1 are
overexpressed in the stromal compartment
of both chronic pancreatitis and pancre-
atic cancer. Proteomic studies have been
carried out to discover proteins that are
differentially expressed between pancrea-
titis and pancreatic cancer [9]. Molecules
that have been observed to be upregulated
in chronic pancreatitis but not in PDACs
include CCL3 and CCL4 [10]. On the
other hand, molecules that are overex-
pressed in PDACs but not in chronic
pancreatitis include annexin A2 and
IGFBP2 [11]. Such molecules could be
tested further, which might prove useful in
distinguishing pancreatic cancer from
chronic pancreatitis. Also, identifying bio-
markers with better sensitivity and speci-
ficity than CA19-9 will significantly im-
prove the diagnosis of pancreatic cancer.
In fact, recent reports have shown that
CEACAM1 and MUC1 indeed possess
higher sensitivity and specificity for diag-
nosis of PDACs than CA19-9, the current
gold standard [12,13].
Molecules Overexpressed in the
Tumor Microenvironment
It is becoming clear that the tumor
microenvironment is involved in initiation,
proliferation, migration, invasion, angio-
genesis, and metastasis of cancers. The role
of the stromal component in pancreatic
cancer progression is also being investigat-
ed, and recent reports provide experimental
evidence to show the effect of the tumor
microenvironment in promoting pancreatic
cancers [14]. The significance of the tumor
microenvironment is also exemplified in a
study where expression of SPARC by
peritumoral fibroblasts was shown to be
Table 1. Summary statistics of the pancreatic cancer biomarker compendium.
Feature Statistics
Total number of published articles read 5,200
Total number of papers referenced in the final catalog 2,325
Total number of genes in the catalog 2,516
Number of genes with mRNA-level expression data 2,309
Number of genes with protein-level expression data 648
Number of genes with both mRNA- and protein-level expression data 441
Number of genes with only mRNA-level expression data 1,868
Number of genes with only protein-level expression data 207
Number of genes that have been tested on clinical samples by immunohistochemistry 386
Number of molecules that are both induced in pancreatic cancer and have been
shown to be present in body fluids
930
Number of molecules that are both overexpressed in pancreatic cancer and have been
shown to be present on the plasma membrane
567
Number of molecules upregulated in precursor lesions 1,094
Number of molecules overexpressed in cancer cells as well as stroma 266
Number of molecules overexpressed in stroma alone 5
doi:10.1371/journal.pmed.1000046.t001
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tients with pancreatic cancer [15]. During
our literature search, in addition to infor-
mation on the overexpression of molecules,
we have also documented data on the
particular cell types where they are overex-
pressed. There are more than 200 mole-
cules in the compendium that have been
reported to be overexpressed in pancreatic
cancer-associated stroma; a subset of these
have been listed in Table F in Table S1. We
reasoned that a large number of molecules
might be specifically overexpressed in the
pancreatic cancer stroma because of the
large stromal compartment in the pancreas
and the frequent occurrence of an intense
stromal reaction in PDACs. Surprisingly, as
illustrated by the set of molecules listed in
Table F in Table S1, most proteins that
were overexpressed in the stroma of
pancreatic cancer tissue were also overex-
pressed in the neoplastic ductal cells.
Galectin 1 and CRISP-3 are among the
minorityof molecules that have beenclearly
described to be overexpressed only in the
stroma, and not the neoplastic cells.
Conclusions
Our efforts at creating this compendium
represent the first step in tackling bio-
markers for pancreatic cancer in a global
and systematic fashion. In fact, it is already
being used by a consortium of investiga-
tors who are developing antibodies against
the 60 most promising targets in PDACs
as part of a new initiative funded by the
Lustgarten Foundation for Pancreatic
Cancer Research. Our compendium also
included data on other, less common
subtypes of pancreatic cancer (Table G
in Table S1 provides a partial list of
molecules). The entire list of molecules
overexpressed in pancreatic cancers that
are included in the compendium is
provided in Table S2. It must be pointed
out that 74% of the molecules in this
compendium are based solely on mRNA
evidence. As is inherent to mRNA-based
methods, especially DNA microarrays, the
data often require subsequent validation
by other methods. Further, several high-
throughput studies carried out to identify
genes that are differentially expressed in
pancreatic cancer have used tissues that
are not microdissected to separate cancer
from stroma. Thus, it is unclear in many
instances if the observed difference in the
expression of a particular gene originates
in the stroma or in cancer cells. This
further underscores the importance of
validating these observations using alter-
native methods by targeted studies.
Fortunately, about 648 molecules that
we present have already been tested at the
protein level (this includes 441 that have
both mRNA and protein evidence) in
individual laboratories, making them
high-priority candidates for further testing.
A significant number of candidate bio-
markers are secreted and membrane-
bound molecules, which makes them
attractive candidates as biomarkers for
early detection. The molecules described
in this catalog can also serve as clinically
relevant targets. For example, they could
be targets for chemoprevention of pancre-
atic cancer in individuals with a strong
family history of pancreatic cancer [16].
The recent demonstration that COX-2 is
overexpressed in PanINs and in IPMNs
suggests that COX-2 inhibitors might be a
reasonable chemoprevention strategy [17].
The candidate biomarkers identified may
also be useful as imaging targets. A
number of the claudins have been shown
to be overexpressed in pancreatic cancer
and are potential markers for early
detection of pancreatic cancer [18]. For
example, iodine-125 radiolabeled anti-
claudin-4 antibody has been employed
for imaging pancreatic cancer using gam-
ma scintigraphy and single-photon emis-
sion computed tomography/computed to-
mography [19]. Finally, the candidate
biomarkers identified may be useful as
therapeutic targets as well. In this regard,
prostate stem cell antigen is a good
example because although it is being
tested as a therapeutic target for the
treatment of prostate cancer, it is also
overexpressed in pancreatic cancer [20].
Challenges and Outlook
Given the explosion of data from
multiple platforms, the information must
be integrated before a systems view of
cancers can emerge. In this regard, we
have used pancreatic cancer as an exam-
ple to create a resource that should serve
as a model for other cancers. Discovering
a single biomarker that would be both
sensitive and specific for cancer of a given
organ might be more difficult than discov-
ering a panel of biomarkers. Identifying
components to be used in such a panel
would require systematic cataloging and
testing of the most promising candidates
that are available. To this end, we have
carried out a systematic curation of the
literature that took approximately over
7,000 person hours. This was an interna-
tional effort and was possible because of
concerted efforts of trained scientists at the
Institute of Bioinformatics, where the
majority of the curation work was carried
out, working closely with several scientists
in the United States. Such database efforts
are crucial for systems biology approaches
to human diseases because the data are
not available in a single location and often
not accessible to those without any bioin-
formatics experience. We feel that a
multipronged approach to cancer will
require not only continued discovery
efforts, but also resources that maximize
what we already know about cancers. Our
future goal is to develop a Web-based
searchable database of all molecular
alterations in pancreatic cancer—from
the genome to the proteome—that will
help initiate a systems medicine approach
to cancer.
Supporting Information
Table S1 Tables A–G. Table A: Partial
list of molecules overexpressed in the
majority of PDACs. Table B: Partial list
of secreted proteins that have been
reported to be overexpressed in pancreatic
cancers at mRNA and protein levels.
Table C: Partial list of plasma mem-
brane-bound proteins reported to be
overexpressed in pancreatic cancers at
mRNA and protein levels. Table D:
Partial list of molecules overexpressed in
precursor lesions. Table E: Partial list of
molecules overexpressed in chronic pan-
creatitis, along with their expression status
in PDAC. Table F: Partial list of molecules
overexpressed in the stroma associated
with pancreatic cancer. Table G: Partial
list of molecules showing elevated expres-
sion in different subtypes of pancreatic
cancer.
Found at: doi:10.1371/journal.pmed.
1000046.s001 (4.52 MB DOC)
Table S2 List of molecules reported to
be overexpressed in pancreatic cancers.
Found at: doi:10.1371/journal.pmed.
1000046.s002 (1.95 MB XLS)
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